Integral Health Asset Management LLC Invests $1.38 Million in Silence Therapeutics plc (NASDAQ:SLN)

Integral Health Asset Management LLC bought a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 200,000 shares of the company's stock, valued at approximately $1,376,000. Integral Health Asset Management LLC owned approximately 0.67% of Silence Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics during the 4th quarter worth about $26,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after buying an additional 5,233 shares during the last quarter. Barclays PLC lifted its holdings in Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after buying an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics during the 4th quarter worth about $69,000. Finally, Virtus ETF Advisers LLC lifted its holdings in Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after buying an additional 6,098 shares during the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. The Goldman Sachs Group decreased their price target on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Chardan Capital decreased their price target on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a report on Friday, May 9th. BMO Capital Markets reduced their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Morgan Stanley reduced their target price on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Stock Up 9.0%

Shares of SLN stock traded up $0.36 during mid-day trading on Friday, hitting $4.37. 281,395 shares of the company's stock were exchanged, compared to its average volume of 300,867. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38. The stock has a market cap of $130.79 million, a price-to-earnings ratio of -2.78 and a beta of 1.20. The stock has a 50-day simple moving average of $3.34 and a two-hundred day simple moving average of $6.01.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. As a group, analysts anticipate that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.